RAD to advance the clinical development of Lantheus innovative radiopharmaceuticals in Australia Initial collaboration will focus on a Phase 1 imaging trialFinancial incentives to be paid to RAD upon ...
RAD to advance the clinical development of Lantheus innovative radiopharmaceuticals in Australia Initial collaboration will ...
A substantial insider activity was disclosed on December 24, as MARKISON, CEO at Lantheus Holdings LNTH, reported the exercise of a large sell of company stock options. What Happened: MARKISON ...
In the interim, Lantheus Holdings’ CEO Brian Markison and President Paul Blanchfield will oversee the research and development responsibilities previously held by Dr. Humphrey. The company maintains ...
Lantheus has begun a search for his successor, it said. Chief Executive Brian Markison and President Paul Blanchfield are filling in as interim leaders of research and development.
In the interim, Lantheus Holdings' CEO Brian Markison and President Paul Blanchfield will oversee the research and development responsibilities previously held by Dr. Humphrey. The company ...
His departure is amicable and not due to any disagreements, and interim leadership of research and development will be handled by CEO Brian Markison and President Paul Blanchfield while a search ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results